

Amendments to the Specification

Please enter the following changes to the specification:

In the Title:

"Nucleic Acid-Antibody Conjugate for Delivering a Foreign Nucleic Acid into in Cells"

In the specification at page 10, replace the paragraph beginning at line 15 as follows:

The term "cleavable peptide" is intended to denote a peptide comprising one or more sequences which can be cleaved with glycolytic and/or proteolytic enzymes, preferably endosomal and/or lysosomal enzymes, such as for example cathepsins and trypsin. According to a particular embodiment, the cleavable peptide of the invention comprises at least one cathepsin B site and/or one cathepsin D site. Preferably, the cleavable peptide comprises a cathepsin B site and a cathepsin D site, separated by at least one amino acid, preferably by at least two amino acids, such as for example glycine; the cleavable peptide of the invention has the sequence: X₁-X₂-F-Y-G-G-F-R- (SEQ ID NO: 1) in which G represents glycine, and X₁ and

X₂ represent amino acids which allow the chemical bonding or attachment of the antibody, such as for example two lysines (K). F-Y represents the dipeptide composed of the amino acids phenylalanine-tyrosine, which can be cleaved with cathepsin D; this sequence may optionally be replaced with L-Y (leucine-tyrosine) (SEQ ID NO: 2), Y-L (tyrosine-leucine) (SEQ ID NO: 3) or F-F (phenylalanine-phenylalanine) (SEQ ID NO: 4). FR represents the dipeptide composed of the amino acids phenylalanine-arginine which can be cleaved with cathepsin B.

In the specification at page 16, replace the paragraph beginning at line 4 as follows:

In another preferred embodiment, the translocation domain is a fragment of *Haemophilus A* hemagglutinin (SEQ ID NO: 5). This fragment of influenza A hemagglutinin (HA) may be modified at its C-terminal end by adding a cysteine or by adding a short peptide sequence terminating with a cysteine, in order to make the cysteine react with the coupling agent, which is preferably APDP.

In the specification at page 27, replace the paragraph beginning at line 1 as follows:

Figure 3 represents the analysis by flow cytometry of the human RCC cells bearing the G250 Ag, collected 7 days after transfection of the cDNA encoding the human CD4 molecule and labeled with a human anti-CD4 mAb. In this way, approximately 20% of the cells express this molecule. The vector used comprised all of the molecules, G250,H1,Ha,cDNA. The sequence of the HA peptide used is as follows:

GLFEAIAGFIENGWEGMIDGGCGSGSYTDIEMNRLGKG (SEQ ID NO: 5).